Alcon (ALC) said Wednesday the US Food and Drug Administration approved its eye drop Tryptyr to treat the signs and symptoms of dry eye disease.
The approval was supported by two phase 3 trials involving more than 930 patients with a history of the condition.
Alcon said it expects to launch Tryptyr in the US in Q3.